Insertional leukemogenesis represents the major risk factor of hematopoietic stem cell (HSC) based gene therapy utilizing integrating viral vectors. To develop a pre-clinical model for the evaluation of vector-related genotoxicity directly in the relevant human target cells, cord blood CD34 + HSCs were transplanted into immunodeficient NOD.SCID.IL2rg −/− (NSG) mice after transduction with an LTR-driven gammaretroviral vector (GV). Furthermore, we specifically investigated the effect of prolonged in vitro culture in the presence of cytokines recently described to promote HSC expansion or maintenance. Clonality of human hematopoiesis in NSG mice was assessed by high throughput insertion site analyses and validated by insertion site-specific PCR depicting a GV typical integration profile with insertion sites resembling to 25% those of clinical studies. No overrepresentation of integrations in the vicinity of cancer-related genes was observed, however, several dominant clones were identified including two clones harboring integrations in the ANGPT1 and near the ANGPT2 genes associated with deregulated ANGPT1-and ANGPT2-mRNA levels. While these data underscore the potential value of the NSG model, our studies also identified short-comings such as overall low numbers of engrafted HSCs, limited in vivo observation time, and the challenges of in-depth insertion site analyses by low contribution of gene modified hematopoiesis. Molecular Therapy-Nucleic Acids (2014) 
Introduction
Hematopoietic gene therapy employing autologous hematopoietic stem cells (HSCs) constitutes an attractive strategy for the treatment of congenital disorders of the hematopoietic system. For severe diseases, it represents the only curative alternative to allogeneic bone marrow transplantation (BMT), particularly if a suitable HLA-matched donor is not available. Current approaches utilize integrating retroviral vectors for the transfer of a functional therapeutic gene copy into autologous HSCs in vitro before they get reinfused into the patient. Groundbreaking clinical studies in life-threatening hematological disorders such as primary immunodeficiencies (reviewed in ref. 1 ) have demonstrated the therapeutic efficacy of hematopoietic gene therapy showing reconstitution of the respective blood lineages with functionally corrected cells, clearance of infections, or independence from replacement therapies. However, in four independent studies, patients developed hematopoietic malignancies following therapy. [2] [3] [4] [5] A causal link between the gene therapeutic intervention and these malignancies was established by the demonstration of the transcriptional activation of known protooncogenes like LMO2, CCND2, BMI1, PRDM16, and MDS-EVI1 by retroviral vector integrations close to or in these genes. However, besides insertional mutagenesis, additional factors such as the preconditioning chemotherapy or the ex vivo culture of the transplanted cells in the presence of cytokines may have contributed to the induction of these malignancies.
In addition to the ex vivo culture of HSCs during gene therapy approaches, the expansion of transplantable HSCs in vitro represents a highly attractive goal given the limited numbers of available donor cells in allogeneic stem cell transplantations, particularly when single cord blood units are used as donor material. Therefore, a plethora of different strategies including the use of novel cytokines, 6 co-culture systems, 7, 8 or small molecules 9 have been evaluated for the expansion of long-term engrafting HSCs. However, prolonged culture with increased proliferation of hematopoietic stem and progenitor cells might raise new safety concerns in the context of gene therapy as cell clones harboring integrations near critical genes may proliferate overly and accumulate additional chromosomal aberrations already in vitro, thereby increasing the overall risk of adverse events for the patients. 10 In this respect, thorough long-term monitoring of integrations in or near critical genes following the reinfusion of gene modified cells is of utmost importance. Linear amplification mediated (LAM)-PCR 11 and derived methods to detect viral integrations [12] [13] [14] in combination with high throughput sequencing technologies allow to comprehensively monitor the clonal repertoire of the gene modified hematopoiesis in the patients, but in the end cannot prevent clonal outgrowth. Thus, highly sensitive and well characterized preclinical models are needed to test integrating viral vectors prior to clinical application. In this context, several murine in vitro 15 and in vivo 16, 17 as well as large animal models 10, [18] [19] [20] have been established and allow for long-term observations.
Because the occurrence of insertional leukemias in the murine syngeneic model is a rare event, the development of clonal dominance serves as readout for the comparison of gene therapy vectors. [21] [22] [23] However, given the inherent differences in the transformation potential between human and rodent cells, 24, 25 the generation of models evaluating the vector-related genotoxicity directly in the relevant human target cells appears highly warranted. Xenotransplantation of gene modified human CD34
+ cells into immune-deficient mouse strains represent an attractive tool to achieve this aim. [26] [27] [28] Although the xenotransplant model allows the evaluation of gene transfer efficacy, 29 there is so far no report on clonal dominance or leukemia induction caused by retroviral insertional mutagenesis in human cells in this model. Therefore, in this study we explored the xenotransplant model for the assessment of genotoxicity after retroviral gene transfer into human HSCs subjected to different in vitro transduction and expansion protocols.
Results

In vitro expansion of CB-CD34
+ cells in different cytokine conditions Pilot experiments (n = 4) were performed to establish the in vitro expansion protocol. In these studies, 1.1-2.0 × 10 5 human CB-CD34 + cells were transduced and expanded in four different cytokine conditions (Table 1 ) for a total of 10 days. The combination of the cytokines SCF, THPO, and FLT3-L (referred to as "STF") represented the baseline standard. The second approach evaluated the combination of G-CSF with STF (referred to as "GCSF"). 19 In addition, two recently proposed HSC expansion protocols using either SCF, THPO, FGF1, IGFBP2, and Angiopoietin-like-5 (referred to as "Angptl5") 6 or the cytokines SCF, THPO, FLT3-L, IL-6, and the small molecule StemRegenin (referred to as "SR1") 9 were investigated. Cultivation in the GCSF cytokine combination yielded the highest proliferation of total cells (121 ± 48 fold), while Angptl5-cultured cells proliferated the least (41 ± 18 fold; Figure 1a) . Likewise the total number of CD34 + cells increased between 8-and 40-fold with the highest expansion observed in the SR1-containing medium (Figure 1b) . Although the relative contribution of CD34 + cells dropped substantially during the 10 days of in vitro culture, it remained highest in the SR1 medium (35.6% ± 1.5% vs. 16.6% ± 2.9% STF, 8.6% ± 1.1% GCSF, 13.7% ± 1.6% Angptl5; Figure 1c ,d) and here also higher CD34 expression levels per cell were observed as measured by the mean fluorescence intensity (Figure 1e ). In agreement with the expansion of CD34 + cells, also the highest number of colony forming cells was present in the SR1 cultures after 10 days. However, the potential of colony formation per cell decreased with increased culture time. In this comparison also SR1 cultured cells had the highest CFU potential, which was significantly higher than in GCSF cultures (Figure 1f,g ). Two independent experiments were carried out resulting in n = 5-6 mice per experimental group ( Table 2) . In both experiments, the transduction efficiency was beyond 90%, independent of the cytokine conditions employed during transduction (Supplementary Figure S1) . In a control group, NSG mice were transplanted with cells transduced and cultured only for 4 days in STF medium (STF-ctrl; n = 6 mice). In all groups, the contribution of human CD45 + leukocytes in the peripheral blood increased over time indicating effective engraftment (Supplementary Figure S2) . After 24 weeks, animals were sacrificed and the human engraftment and lineage contribution in the different hematopoietic tissues were determined by FACS analysis (Figure 2 and Supplementary Figure S3 ). In all groups, contribution of human cells to overall hematopoiesis varied substantially. There was a tendency towards lower BM engraftment and less human cell contribution to the blood in mice of the GCSF and STF-ctrl groups (Figure 2a,b) ; however, this was not significant by Kruskal-Wallis analysis across the groups, P = 0.5; (pairwise test in the blood: STF-ctrl versus STF P = 0.08, GCSF versus STF P = 0.1, Mann-Whitney test). In these mice, also human T-cell contribution was low (Supplementary Figure  S4) in line with an insufficient thymus repopulation as well as peripheral blood mobilization observed in these groups. In the reconstituted thymi, human T-cell development was normal with human CD4/CD8 double-and single-positive T-cells detectable (Supplementary Figure S4) .
In vitro
The contribution of retrovirally transduced cells to hematopoiesis was variable but higher in the second experiment (Supplementary Figure S5) . The number of GFP positive cells detected by FACS in individual mice correlated well with the detected vector copy number as measured by quantitative PCR (Supplementary Table S1 ). Over the course of our study, blood cell counts stayed well within the physiological range without any signs of abnormalities (Supplementary Figure S6) . Furthermore, no major hematological abnormalities were detected by histopathological analysis of mouse organs (Supplementary Figure S7) . In summary, engraftment of gene modified human CB-CD34 + cells was variable between mice but there was a tendency of improved engraftment after in vitro expansion in STF, Angptl5 or SR1 as compared to GCSF conditions or transplantation of unexpanded cells.
Typical GV integration pattern without selection of clones with integrations near cancer-associated genes in vivo Linear amplification-mediated (LAM) PCR 11 and 454-pyrosequencing were performed to detect GV vector integration 100 ng/ml SCF 100 ng/ml SCF 100 ng/ml Angptl-5 100 ng/ml SCF 50 ng/ml THPO 100 ng/ml TPHO 100 ng/ml IGFBP2 100 ng/ml TPHO 100 ng/ml FLT3-L 100 ng/ml FLT3-L 10 ng/ml SCF 100 ng/ml FLT3-L 100 ng/ml G-CSF 20 ng/ml THPO 100 ng/ml IL-6 10 ng/ml FGF-1 1 µmol/l SR1 SCF, stem cell factor; THPO, thrombopoietin; FLT3-L, FMS-like tyrosine kinase 3 ligand; G-CSF, granulocyte colony stimulating factor; Angptl-5, angiopoietin-like 5; FGF-1, fibroblast growth factor-1; IL-6, interleukin 6; SR1, Stemreginin 1.
sites. A combination of three restriction enzymes was used for LAM-PCR to detect insertion sites in the BM of 29 transplanted mice and 6 in vitro samples collected before transplantation (pre-TX). A total of 1615 integrations (1, 197 in pre-TX, 418 in BM samples) were retrieved displaying an insertion profile typical of a GV vector with integrations clustering around the transcription start sites (TSS; Figure  3a ). Median distance to the TSS was 0.7 kb and the frequency of intronic integrations was 62.8% with no significant difference between the pre-TX and the in vivo samples for these parameters. We did observe, however, a significantly lower number of insertions within a 10 kb distance to the TSS for the in vivo samples arguing against an in vivo selection for clones with insertions close to the TSS. Between 1 and 48 individual integration sites were recovered per mouse (Supplementary Table S2 ) and the number of integrations correlated directly to the human CD45 + GFP + cell engraftment in the BM (Spearman r = 0.52, P = 0.003; Figure 3b ). 
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As the use of restriction enzymes may be problematic for the detection of certain insertion sites and could potentially interfere with the quantification by sequence reads, 30 we also performed non-restricted (nr)LAM 13 and re-free LAM PCRs. 12 Due to the lower sensitivity of these methods, this analysis was only performed in mice with high numbers of gene modified cells in the BM. Here, 31 insertions in six mice were recovered by the re-free LAM PCR and 55 insertions in three mice by the nrLAM-PCR method (Supplementary Table S3 ).
These 86 insertions were allocated to 74 unique genes, out of which 18 (24%) overlapped with those detected by the conventional LAM-PCR, but only three (4%) were identified by both non-restricted methods. Based on eight mice analyzed by repeated LAM and non-restricted LAM-PCRs, the overall pool size was calculated to 135 insertions per mouse using Chapman estimation (Supplementary Figure S8) .
To identify a potential selection of integrations in or close to known proto-oncogenes we compared the integrations in 31 the Network of Cancer-related Genes (NCG) 32 and a compiled Cancer Gene List from the Bushman lab (www.bushmanlab.org/ links/genelists). There were no significant difference between the individual in vitro (χ 2 P = 0.8979) or in vivo groups (χ 2 P = 0.4587). In all groups, a reduction of hits close to cancer related genes was observed in vivo; however, this is not significantly different for any of the groups (Fisher's exact test, P = 0.0666 (Figure 3c) ). This was also true for the fold changes in hits close to oncogenes for each mouse calculated separately (Supplementary Figure S9) . These data argue against a general enrichment of clones with insertions close to proto-oncogenes in vivo or during in vitro expansion. 
Insertion sites in the NSG model recapitulate data from clinical trials
We further compared the insertions identified in our study with the integration data from five clinical trials and three preclinical studies using GV reported by Deichmann and colleagues. 33 We found a total overlap of 217 (21.4%) insertions with the Deichmann study. In addition, among all insertions recovered in our study, 45 common insertion sites (CIS) of 4th or higher order, as defined by Wu and colleagues 34 were detected ( Table 3 ) with nine of these CIS observed near or in cancer-related genes. For these CIS again a considerable overlap with insertions reported by the Deichmann study (13/45, 29%) was observed. Furthermore, the ANGPT1 locus was identified as a CIS of higher order (6th in our analysis; 5th in the Deichmann study). These results underline the fact, that clinically relevant insertion sites can be retrieved in the humanized mouse model.
Human dominant clones arise in NSG mice
As we expected higher sequence reads of integration sites in dominant clones compared to clones of low abundance, we analyzed the occurrence of high read insertions in the mice. Although high read insertions (>100 reads) were detected in all transplant groups (23/418 total integrations for LAM-PCR analysis (Figure 4a ) and 16/86 integrations for nrLAM and referee LAM-PCR) there was no significant difference in their occurrence between the groups (Supplementary Figure S10) .
To verify the presence and quantify the contribution of clones with specific insertion sites, we performed insertion site-specific (IS) quantitative (q)PCRs on BM-DNA of six mice with varying human engraftment but good contribution of transgenic cells (Figure 4b) . We selected eleven integrations of which five had particularly high read counts. We confirmed four of the high read insertions by IS-qPCR in the BM (ANGPT1, ANGPT2, EHD1, TXNDC2). One insertion site was detected as dominant clone although the read counts did not predict this (PMVK). In three cases, the estimation of abundance by insertion site analysis was >30-fold different than by IS-qPCR (ERMP1, CD3EAP, ARHGEF, Supplementary Table S4 ). In general, IS-qPCR detected higher contributions to the transduced hematopoiesis in two and lower in nine cases (Figure 4c and Supplementary Table S4), indicating that the sequence reads mostly overestimated the abundance of clones.
In a next step, we tried to quantify these insertions in the peripheral blood over time by IS-qPCR. Here, in mouse M69 a clone with an integration in the fourth intron of ANGPT1 became progressively dominant in the gene-modified human hematopoiesis (2.1-29.4%; week 9-24, Figure 4d ). In the same mouse, we further detected a clone with an insertion site close to EHD1 with almost the same kinetics as the ANGPT1 clone indicating that both insertions probably were contained in the same cell clone. A dominant clone harboring an integration in reverse orientation 5.8 kb upstream of the ANGPT2 gene progressively contributed to human hematopoiesis in mouse M53 (Figure 4e) . In mouse M65, a clone with an integration 387 bp downstream of the TSS of PMVK with increasing blood contribution was quantifiable as well as a low abundance clone with an insertion close to TXND2 which was dominant in the BM (Figure 4f) . Two additional integrations-C16orf7 (mouse M70) and ERMP1 (mouse M63)-were tracked over time in blood samples albeit their contribution to overall human hematopoiesis was low (Figure 4g,h) . Thus, we were able to validate integration sites by IS-qPCR and to track clones by their insertion site in the blood. We also identified dominant clones with increasing contribution to gene modified hematopoiesis over time.
Viral vector integrations caused deregulated expression of human cellular genes
To investigate whether the occurrence of dominant clones led to deregulation of gene expression due to vector integration, we analyzed expression of ANGPT1, ANGPT2, and PMVK in the three animals harboring these integrations. The mRNA levels of ANGPT1 in mouse M69 were significantly reduced in comparison to other transplanted NSG mice not containing this integration (Figure 5a , left panel) and CD34
+ control cells. The integration site was located in the fourth intron in sense orientation (Figure 5b) , which was also a CIS in our study, and may have interfered with cellular splicing; however, we were not able to detect fusion transcripts between the vector and gene. Sequencing of ANGPT1 mRNA detected alternative splice forms lacking exon5 coding sequence, arguing for altered splicing. In contrast, in mouse M53 the GV integration caused a significant upregulation of the ANGPT2 mRNA levels (~50 times, Figure 5a , middle panel) which was in agreement with the typical GV integration close to the promoter, favoring enhancer-mediated interactions between the vector enhancer and the cellular promoter (Figure 5c ). PMVK expression in mouse M65 was not significantly deregulated compared to the other mice (Figure 5a, right panel) . The inability to detect altered gene expression in this case may in part be due to the low contribution of the human hematopoiesis in this specific mouse, although the clone was dominant within the human transduced cells. 
Discussion
In this study, we addressed the question whether we could detect genotoxic events in the humanized mouse model. For transduction, we employed a GV LTR vector with a known genotoxic potential expressing eGFP as a marker gene 16 8 was, therefore, designed to test the potential of the humanized mouse model to read out gene therapy-related genotoxic events. The engraftment with gene modified human cells was efficient but highly variable between mice and thus made the discrimination between the different media conditions used for in vitro expansion difficult. Specifically, the superior in vitro expansion of CD34 + cells by SR1 was not reflected by better engraftment in NSG mice. There was, however, a tendency of improved engraftment of cells expanded in STF, Angptl5, or SR1 condition in contrast to expansion in GCSF. While the transplantation of fewer cells may have yielded more distinct differences between expansion conditions, 9 this was incompatible with the aim of our study, as in our model the assessment of genotoxicity relies on a high number of transduced and transplanted CD34 + cells. Employing LAM-PCR, we recovered 418 in vivo-insertion sites with one to 48 per mouse, on the basis of an estimated pool of ~135 insertions per mouse. In comparison, Greene and colleagues reported 82, 38, and 27 unique insertion sites in three NSG mice, 36 but in this study, four times more CD34 cells were transplanted. Based on limiting dilution assays 37 or recent studies employing barcoding strategies in the NSG model that estimated the number of long-term engrafting HSCs to only 0.02% of cord blood CD34 + cells, 38 we can estimate a number of 10-25 long-term repopulating HSCs per mouse in our experiments (not taking into account a potential effect of the in vitro culture on this number). As we identified the insertion sites 24 weeks after transplantation, we can assume that our analysis was focused on long-term repopulating HSCs.
We performed nrLAM-and referee LAM-PCR to correct for the bias introduced by the use of restriction enzymes. 30 Although these methods have the disadvantage of lower sensitivity and a higher need for input DNA compared to the conventional LAM-PCR, we detected insertion sites not identified by conventional LAM-PCR (e.g. in ANGPT1). However, the overall number of individual insertion sites per mouse detected by the non-restricted methods was lower than from the conventional LAM-PCR. Importantly, only the use of insertion site-specific qPCR allowed us to unequivocally determine clone size. Thus, among the ten investigated insertion sites, only in half of them a dominant contribution to human hematopoiesis was confirmed. This recapitulates our recent results in the humanized mouse model using MGMTexpressing vector 27 and highlights the technical limitations associated with quantitative analysis of clonality based on read counts also observed in other studies. [39] [40] [41] Our data suggest, however, that the read count approach represents a valid selection criterion for further analysis.
Most importantly, our study provides clear evidence that clonal dominance within the human hematopoiesis can be detected and quantified in the xenograft model. This is in contrast to the published data for the evaluation of a clinical grade vector for the treatment of Wiskott Aldrich Syndrome 42 and most likely reflects the increased mutagenic potential of our LTR-driven GV vector in combination with the prolonged in vitro expansion culture.
We detected dominant clones with an activating integration closely upstream of the TSS of ANGPT2 in one, and downregulation of ANGPT1 with the vector integration in the fourth intron in the other. Both angiopoietins bind to the Tie2 receptor which is expressed on long-term repopulating HSCs. A role of Tie2 in maintaining HSC quiescence and self-renewal was demonstrated in mouse models. 41 The overexpression of ANGPT1 in the BM niche during steady-state-hematopoiesis increased the number of LSK cells. 40 However, our experiments were based on the in vitro transduction, culture and transplantation of HSCs and their hematopoietic reconstitution after transplantation. The reciprocal regulation of the ANGPT genes as seen in our study may be benificial in this situation. However, the function of ANGPT2 in hematopoiesis is not well examined. Both ANGPTs are secreted from BM niche cells and only at very low levels expressed in HSCs under normal conditions (Supplementary Figure S11) .
Following the contribution to the gene modified hematopoiesis in the blood, the ANGPT1, ANGPT2, EHD1, and PMVK clones progressively took over the gene modified compartment, indicating a growth advantage over the other clones. We, therefore, confirmed three dominant clones in thirty mice and calculated an incidence of clonal dominance of 2 × 10 -6
per transplanted cell and 3.3 × 10 -6 per vector insertion. We did not detect leukemic transformation of human cells in the xenograft model which in the murine BMT model using the same gammaretroviral vector occurred with an estimated frequency of <2 × 10 -7 per transplanted cell 43 and up to 10 -6
after high dose transduction and in vitro expansion of transduced cells before transplantation. 16 Clonal dominance in the murine model occurred in almost every mouse when using the gammaretroviral LTR vectors containing strong enhancer/ promoter elements as used in our study; 44, 45 however, in general, more stem cells are transplanted in the murine model. From these estimations, it can be concluded that the occurrence of clonal dominance in the humanized mouse model was only slightly lower than in the murine model, but that the low number of initially transduced and transplanted CD34 + cells precluded a comprehensive comparison between our groups. Furthermore, we did not observe leukemic transformation of human cells. This can be explained by the inherent differences between human and murine cells in respect to transformation, 24 but complicates the development of humanized genotoxicity models. In addition, although the observation time was long enough to detect clonal dominance, for leukemic transformation longer observation times, including secondary transplantations, may be needed. Taken together, our study sheds light on the current obstacles that need to be addressed for efficient use of humanized mouse models to assess genotoxicity. It further supports the cautious interpretation of gene therapy safety analysis in respect to genotoxicity in the humanized mouse model based on a similar study design.
Materials and Methods
Virus production. Human CD34 + cells were transduced with the gammaretroviral vector RSF91.eGFP.pre* 46 pseudotyped with the modified feline endogenous virus glycoprotein RD114/TR. 47 Infectious viral particles were produced with a split packaging system in human embryonic kidney 293T cells 48 and concentrated by ultracentrifugation, resuspended in StemSpan (Stemcell Technologies, Vancouver, Canada) and stored at −80 °C.
CD34
+ cell isolation, culture, and transduction. Cord blood (CB) samples were obtained from the Hannover Medical School following written consent of the donors as approved by the Hannover Medical School local ethics committee. Total nucleated cells were isolated by a Ficoll gradient followed by enrichment for CD34 + cells employing MACS purification (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Isolated cells were frozen until further usage. CB-CD34 + cells were cultured in StemSpan medium supplemented with 1% penicillin/streptomycin and one of four cytokine combinations using hSCF, hTHPO, hFLT3-L, hGCSF, hIGFBP2, hAngptl5, hFGF-1, and hIL6 (PeproTech, Rocky Hill, CT). The StemRegenin compound (Cellagen Technology, San Diego, CA) was used at a concentration of 1 µmol/l as described. The experiments were done in two cohorts with transplantation performed on different days. Each cohort was transplanted from the same pool of donor CB-CD34 + cells but two different pools were used for the two cohorts. Starting at 6 weeks post TX, blood samples were taken in intervals of 3 weeks for blood counts, flow cytometric analysis and DNA isolation. Mice were sacrificed at 24 weeks, cells from the peripheral blood, BM and thymus isolated and analyzed by flow cytometry using antibodies as specified in Supplementary Materials and Methods.
Linear amplification mediated (LAM)-PCRs and high throughput sequencing.
Conventional, restriction enzyme-free (refree) and non-restrictive (nr) linear amplification mediated (LAM)-PCR were performed as described earlier. [11] [12] [13] For further information, see Supplementary Materials and Methods.
Insertion site-specific qPCR and qRT-PCR. Individual vector integrations were validated using reverse primers specific for the genomic region designed according to the 454-sequences, the NCBI BLAST search results and the NCBI reference sequences. The LTR primer located at the 5'end of the LTR (JM354) from the nested PCR step during the LAM-PCR served as the forward primer for validation of all integration sites. Subsequently, real-time TaqMan PCR (Life Technologies GmBH, Frankfurt, Germany) was carried out on all the PB samples collected at different time points using a StepOnePlus (Applied Biosystems, Carlsbad, CA). Additionally, the VCN was determined using primers detecting the woodchuck posttranscriptional element (PRE) and polypyrimidine tract-binding protein 2 (PTBP2) as an internal reference for both quantitative PCRs (qPCRs). All qPCRs were performed in triplicates. A plasmid standard harboring sequences for the residual part of the gammaretroviral LTR, PRE, and PTPB2 was used for the quantification (see Supplementary Materials and Methods for the list of all primers).
Quantitative RT-PCR was done to evaluate gene expression in total RNA isolated from the BM using Quantitect primer assays (QIAGEN) and quantified using SYBR Green on the StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA). Expression of beta-ACTIN served as control.
Bioinformatic analysis of viral integration sites. Post-sequencing data processing was carried out with customized PERL (Practical Extraction and Report Language) and EXCELbased VBA (Visual Basic for Application) scripts as described before. 27, 39, 50 For sequence alignment the freely accessible MAVRIC (Methods for Analyzing Viral Integration Clusters) online tool was employed (http://mavric.erasmusmc.nl/index. php). 51 A detailed description of data procession and the basic parameters used for MAVRIC are provided in the Supplementary Materials and Methods.
Statistical tests. Statistical significance was determined by non-parametric t-test, two-way analysis of variance test and Spearman's rank correlation. Figure S6 . Peripheral blood cell counts. Figure S7 . Histopathological analysis of different tissues. Figure S8 . Pool size calculation by Chapman Estimation. Figure S9 . Fold change of insertion sites close to oncogenes in each mouse. Figure S10 . Number of reads per insertion site for each mouse. Figure S11 . Expression of Tie1, Tie2, ANGPT1 and ANG-PT2 in CD34+ cells and the mice M53 and M69. Table S1 . Overview of transplanted cell numbers and vector copies per mouse. Table S2 . Overview of the insertion site recovered by LAM-PCR in transplanted NSG mice. Table S3 . Overview of the insertion site analysis using nr-LAM and referee LAM PCR. Table S4 . Correlation of sequence reads and quantification by IS-qPCR. Materials and Methods.
